DiaceuticsLSE:DXRX +1.04%91 Gross Margin % is 81.23% as of Dec. 2025, which is 2% above its 10-year median of 79.31. GuruFocus rates LSE:DXRX with a GF Score™ of 91/100 and a GF Value™ of £1.91 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 630 Healthcare Providers & Services companies, Diaceutics ranks better than 88.89% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Diaceutics's Gross Profit for the
six
months ended in Dec. 2025 was £19.39 Mil. Diaceutics's Revenue for the
six
months ended in Dec. 2025 was £23.87 Mil. Therefore, Diaceutics's Gross Margin % for the quarter that ended in Dec. 2025 was 81.23%.
The historical rank and industry rank for Diaceutics's Gross Margin % or its related term are showing as below:
LSE:DXRX'
s Gross Margin % Range Over the Past 10 Years
Min: 57.86 Med: 79.31 Max: 87.91
Current: 81.9
During the past 10 years, the highestGross Margin % of Diaceutics was 87.91%. The lowest was 57.86%. And the median was 79.31%.
LSE:DXRX's Gross Margin % is ranked better than 88.89% of 630
companies
in the Healthcare Providers & Services industry
Industry Median: 40.075
vs LSE:DXRX: 81.90
Diaceutics had a gross margin of 81.23% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Diaceutics was 1.30% per year.
Diaceutics (LSE:DXRX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Diaceutics had a gross margin of 81.23% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Diaceutics Gross Margin % Related Terms
Diaceutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Diaceutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:DXRX vs VEEV, BTSG, TEM: Gross Margin % Comparison
For the Health Information Services subindustry, Diaceutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Diaceutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Diaceutics (LSE:DXRX) has a Gross Margin % of 81.23% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Diaceutics and its competitors. This is near median its historical median of 79.31. Over the past decade, Diaceutics' Gross Margin % has ranged from 57.86 to 87.91. According to the industry distribution chart, Diaceutics ranks #70 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 11.1%.
Is Diaceutics' Gross Margin % too high?
Diaceutics' current Gross Margin % of 81.23% is near median its 10-year median of 79.31. Over the past 10 years, this metric has ranged from a low of 57.86 to a high of 87.91. The Healthcare Providers & Services industry median Gross Margin % is 40.08. Diaceutics' value of 81.23% is 102.7% above this industry median. Based on the distribution chart, Diaceutics ranks #70 out of 630 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diaceutics has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Gross Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #70 out of 630 companies for Gross Margin %. This places Diaceutics in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 40.08. Diaceutics' value of 81.23% is 102.7% above this benchmark. Historically, Diaceutics' own Gross Margin % has ranged from 57.86 to 87.91 over the past decade. While the company's 10-year median is 79.31 vs. the industry median of 40.08, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.08, based on 630 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Gross Margin % of 81.23% is 102.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Gross Margin % is 81.23%, which is near median its own 10-year median of 79.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (LSE:DXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is £1.91, compared to a current price of £1.46 — trading 23.6% below its estimated fair value. The current Gross Margin % is 81.23%, which is near median its 10-year median of 79.31 and 102.7% above the Healthcare Providers & Services industry median of 40.08. Diaceutics' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Diaceutics (LSE:DXRX), the current Gross Margin % is 81.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (LSE:DXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of £1.46 is trading 23.6% below its estimated GF Value™ of £1.91.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for LSE:DXRX:
Gross Margin %: 81.23% (near median its 10-year median of 79.31)
GF Value™: £1.91 vs. price of £1.46 (23.6% below fair value)
Industry Position: 102.7% above the Healthcare Providers & Services median (#70 of 630)
No single metric tells the full story. See the LSE:DXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
91GF Score
Get the complete analysis for LSE:DXRX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:DXRX has been successfully added to your 
